Medical Care-Related Decisions among Patients Diagnosed with Early Stage Malignant Brain Tumor: A Qualitative Study

Numata, Hanako; Noguchi‐Watanabe, Maiko; Mukasa, Akitake; Tanaka, Shota; Takayanagi, Shunsaku; Saito, Nobuhito; Yamamoto‐Mitani, Noriko

doi:10.1177/2333393620960059

Cited by 2 publications

(2 citation statements)

References 44 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our review identified cancer anxiety as a strong barrier 22,30 . Numata et al showed in their research on early stage malignant brain tumour that patients experiencing anxiety during treatment decision-making are often driven by the fear of uncertainty of prognosis, their future QoL, and loss of the self 63 .…”

Section: Patient-related Criteriamentioning

confidence: 99%

The Current Evidence for Factors that Influence Treatment Decision Making in Localized Kidney Cancer: A Mixed Methods Systematic Review

et al. 2021

View full text Add to dashboard Cite

Introduction: With a growing number of treatment options for localised kidney cancer, patients and health care professionals have both the opportunity and the burden of selecting the most suitable management option. This mixed method systematic review aims to understand the barriers and facilitators of the treatment decision-making process in localised kidney cancer. Methods: We searched PubMed, Embase, and Cochrane Central databases between 1st of January 2004 and 23rd of April 2020 using the JBI Manual for Evidence Synthesis and the Preferred Reporting Items for Systematic Review and Meta-analysis statement. We identified 553 unique citations, of these 511 were excluded resulting in 42 articles included for synthesis. The Purpose, Respondents, Explanation, Findings and Significance and the Strengthening the Reporting of Observational Studies in Epidemiology checklist were applied. Results: The key themes describing barriers and facilitators to treatment decisionmaking were identified and categorised into three domains: (1) kidney cancer specific characteristics; (2) decision-maker related criteria; and (3) contextual factors.The main facilitators identified within these domains were: size at diagnosis, age, comorbidities, BMI, gender, nephrometry scoring systems, biopsy, socio-economic status, family history of cancer, year of diagnosis, geographic region and practice pattern. The key barriers were race, gender, patient anxiety, low confidence in diagnostic and treatment options, cost of procedure and practice patterns.

show abstract

Section: Patient-related Criteriamentioning

confidence: 99%

The Current Evidence for Factors that Influence Treatment Decision Making in Localized Kidney Cancer: A Mixed Methods Systematic Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The simplified disease progression scale (FOP-Q-SF) [ 6 ] score, quality of life (QLQ-C30) score, social support scale (SSRS) [ 7 , 8 ], hospital anxiety and depression scale (HADS) [ 9 ] score, and patient dignity inventory (PDI) [ 10 ] scores were compared between the two groups before and after the intervention.…”

Section: Methodsmentioning

confidence: 99%

Current Status of Fear of Disease Progression in Patients with Advanced Cancer and Usefulness of Dignity Therapy Intervention

Zhang

Zhou

et al. 2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

With changes in lifestyle and an increase in bad health habits, cancer has become a noncommunicable and frequently occurring disease that poses a serious threat to human life. Cancer is associated with high rates of morbidity and mortality worldwide. As a major negative life event, advanced malignancies lead to strong mood swings in most patients. Furthermore, various internal and external factors can have a huge impact on patients’ physical and mental health and put them in a stressful situation, causing a series of psychological stress responses. To explore the degree of fear of disease progression in patients with advanced cancer and the usefulness of dignity therapy. Overall, 120 patients with advanced malignant tumors admitted to Shijiazhuang No. 1 hospital between January 2019 and January 2020 were enrolled. The selected patients were divided into the test and control groups (60 people per group) using a random number table. All patients received basic treatment. Patients in the trial group also received dignity therapy. The intervention period was 4 weeks. Simplified scales were used for assessing disease progression (FoP-Q-SF) and quality of life (QLQ-C30) before and after the intervention, and the scores were compared between the groups. After the intervention, the degree of fear in the experimental group was lower than that of the control group. Cognitive function, emotional function, and the scores of the overall health status of the experimental group were higher than those of the control group. Additionally, the scores of fatigue, insomnia, loss of appetite, and diarrhea in the experimental group were lower than those of the control group ( P < 0.05). The social support level scale scores, depression scores, hospital anxiety and depression scale scores, and patient dignity inventory scores of the experimental group were lower than those of the control group ( P < 0.05). Patients with advanced malignant tumors have fear, anxiety, and depression related to disease progression. Dignity therapy is useful for improving the patients’ quality of life, increasing dignity, and enhancing social support.

show abstract

Medical Care-Related Decisions among Patients Diagnosed with Early Stage Malignant Brain Tumor: A Qualitative Study

Cited by 2 publications

References 44 publications

The Current Evidence for Factors that Influence Treatment Decision Making in Localized Kidney Cancer: A Mixed Methods Systematic Review

The Current Evidence for Factors that Influence Treatment Decision Making in Localized Kidney Cancer: A Mixed Methods Systematic Review

Current Status of Fear of Disease Progression in Patients with Advanced Cancer and Usefulness of Dignity Therapy Intervention

Contact Info

Product

Resources

About